Company news
Blossomhill Therapeutics, Inc. (NASDAQ:BLSM) news
Blossomhill Therapeutics, Inc. news releases on 6ix. Latest, Sep 18, 2026: BlossomHill Therapeutics Reports Second Quarter 2026 Financial Results
Press releases & updates
BlossomHill Therapeutics Reports Second Quarter 2026 Financial Results
September 18, 2026
BlossomHill Therapeutics to Present at the 8th Annual RAS-Targeted Drug Development Summit & H.C. Wainwright 28th Annual Global Investment Conference
September 3, 2026
BlossomHill Therapeutics to Present Updated Data from Ongoing Phase 1/2 SOLARA Trial of its Macrocyclic OMNI-EGFR™ Inhibitor, BH-30643, in EGFR-mutant NSCLC at the 2026 World Conference on Lung Cancer
September 1, 2026
BlossomHill Therapeutics Announces FDA Fast Track Designation for BH-30643, a Macrocyclic OMNI-EGFR Inhibitor for the Treatment of Advanced EGFR C797S-positive NSCLC
August 19, 2026
BlossomHill Therapeutics Announces FDA Fast Track Designation for BH-30643, a Macrocyclic OMNI-EGFR™ Inhibitor for the Treatment of Advanced EGFR C797S-positive NSCLC
August 18, 2026
BlossomHill Therapeutics Announces Pricing of Upsized $150 Million Initial Public Offering
August 5, 2026